FORT WORTH, Texas, Dec. 16 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today that its Resorbable Orthopedics operating subsidiary is moving toward productization of its patented orthopedic bone void fillers. The company currently anticipates products to be introduced in Q3 2010, to the bio-products market, estimated to be a multi-billion dollar international market.
"Resorbable Orthopedics has patented technologies that include a resorbable bone wax and a delivery system for orthopedic bone void fillers that were previously unheard of. Orthopedic disorders are expanding internationally into a multi-billion dollar market," said Barry Constantine, founder of Resorbable Orthopedics LLC. "These new era biotechnology products are well timed solutions in a healthcare environment where there is a great need for safer and more affordable solutions to manage bone wound healing and thereby offer a better quality of life at an affordable price. Market entry is expected in 3rd quarter 2010 subject to initiation and completion of certain medical certifications."
"Over the past year we have assembled a national sales force of over 40 independent representatives as well as assembled an extensive international distribution channel for our core CellerateRx® product which targets an international market in excess of 2 billion dollars" stated WNDM CEO Scott Haire. "WNDM has acquired Resorbable Orthopedics to seek to gain a foothold within the international bioproducts market by utilizing our demand side marketing program and extensive WNDM infrastructure; Resorbable's orthopedic biomaterials products complement WNDM's existing proven CellerateRx wound management products and expands the company's biomaterials product portfolio."
For Wound Management Technologies Shareholder Information please call 954-357-0614.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida is a rapidly growing provider of specialty medical products and advanced biotechnology solutions. The Company is following the lead of NASDAQ Biotech Stock INDEX leaders such as Celgene (CELG) http://www.celgene.com, Geron (GERN) http://www.geron.com, and Human Genome Sciences (HGSI) http://www.hgsi.com by working to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering fields. WNDM also has an interest in Cancer Treatment. For more information on the Company please visit http://www.woundmanagementtechnologies.com or call our shareholder information department at 954-357-0614.
"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Further Information: Shareholder Relations - Communications Ronnie Ambrose 954-357-0614
SOURCE Wound Management Technologies, Inc.
|SOURCE Wound Management Technologies, Inc.|
Copyright©2009 PR Newswire.
All rights reserved